EPO906 Therapy in Patients With Advanced Colorectal Cancer

Phase 2

Completed

• Conditions: Colonic Neoplasms; Colorectal Neoplasms

• Registration Number: NCT00035087
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-05
• Study First Submitted: 2002-05-02
• Study First Submitted QC: 2002-05-02
• Study First Posted: 2002-05-03
• Primary Completion: 2003-03
• Study Completion: 2003-03
• Status Verified: 2013-12
• Last Update Submitted: 2013-12-03
• Last Update Posted: 2013-12-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Tumor response as assessed by radiologic techniques and/or physical examination based on Response Evaluation Criteria in Solid Tumors (RECIST)

Secondary Outcome Measures

Name	Time	Method
Time to progression
Overall survival

Trial Locations

Locations (1)

Cancer Institute of New Jersey (CINJ); 🇺🇸 New Brunswick, New Jersey, United States